1 Development of autoimmune thyroid disease (AITD) including Graves' disease (GD) and 2 Hashimoto's thyroiditis (HT) is related to expression of HLA-DRB1*0301(DR3). The 3 extracellular domain (ECD) of human TSH receptor (hTSH-R) is a crucial antigen in GD. hTSH-4 R peptide 37 (AA 78-94) is an important immunogenic peptide in DR3 transgenic mice. 5 In the current study, DR3 transgenic mice were immunized to recombinant hTSH-R-ECD 6 protein or peptides. Serum anti hTSH-R protein antibody, or anti hTSH-R peptide antibodies were 7 titrated by ELISA. Further, a mutant hTSH-R 37 (ISRIYVSIDATLSQLES: 37m), in which DR3 8 binding motif position 5 was mutated V>A, and position 8 Q>S, was synthesized. 37m was 9 predicted to bind to HLA-DR3, but not bind to T-cell receptors. DR3 transgenic mice were 10 immunized to hTSH-R 37 and 37m. 11 Mice immunized to hTSH-R-ECD protein developed strong anti hTSH-R antibody, and 12 the antisera reacted strongly with hTSH-R peptides 1 to 5 (AA 20-94), sequences recognized as B-13 cell epitopes that reacted with human TRAb. In addition, the antisera recognized hTSH-R 14 peptides 21(258-277), 41(283-297), 36(376-389), and 31(399-418). Strikingly, antisera raised to 15 hTSH-R peptide 37 bound hTSH-R peptides 1-7(AA 20-112), 10(132-50), 33(137-150), 41, 16 23(286-305), 24(301-320), 36, and 31, as well as to hTSH-R-ECD protein. Both antibody titers to 17 hTSH-R 37, and reaction of splenocytes to hTSH-R 37, were significantly reduced in mice 18 immunized to hTSH-R 37 plus 37m, compare to mice immunized to hTSH-R 37 alone.
Introduction 1
Autoimmune thyroid disease (AITD) is an organ specific autoimmune disease. Graves' 2 disease (GD) and Hashimoto's thyroiditis (HT) are the major components of AITD. Thyrotropin 3 receptor (TSH-R) is one of the well-known target antigens in GD, and also often serves as antigen 4 in HT ( 1 ) . Ectodomain of TSH-R (TSH-R-ECD) mediates various immune responses in the 5 development of GD ( 2 ), and multiple epitopes are thought to exist( 3-6 ).
6
Shed TSH-R-ECD is endocytosed into antigen presenting cells (APCs), and processed to be 7 presented on the surface of APCs as HLA-DR-epitope complexes.
These complexes 8 arerecognized by CD4 + T-cells and positive signals for B-cell proliferation aretransmitted.
9
Subsequently, anti-TSH-R antibody is secreted by B-cells. Hyperthyroidism is induced by anti 10 TSH-R antibody that stimulates TSH-R. HLA-DRB1*0301(DR3)( 7 ), CTLA-4( 8 ), TSH-R( 9 ), 11 FCRL3( 10 ), PTPN22( 11 ), and other genes were found to be associated with GD. In addition, HD 12 is also related to inheritance of HLA-DR3( 7 ).
13
In our previous study, hTSH-R peptide 37 (AA78-94: ISRIYVSIDVTLQQLES) was 14 demonstrated to be one of the strongest T-cell epitopes in HLA-DR3 transgenic mice, and was an 15 important epitope in the early phase of the immunogenic reaction ( 5 ), however, little information 16 is known about B-cell epitopes using DR3 transgenic mice immunized to hTSH-R-ECD protein or 17 peptides.
18
In an HLA molecule, the anchoring side chains of the peptides (positions 1, 4, 6, 7, and 9) 19 bind in the HLA-DR binding groove. Side chains of amino acids in positions 2, 3, 5, and 8 are 20 believed to contact the T cell receptor (TCR), activate CD4 + T-cells, and eventually B-cells are 21 driven to produce antibodies (12).
22
Many studies showed immune suppression by using altered ligand peptides (ALP) in 23 autoimmune diseases. For example, mutated MBP peptides were found to antagonize T-cell reactions in Multiple sclerosis ( 13 ). To induce tolerance of CD4 + T-cells by attenuating binding to 1 TCR, we designed a mutated hTSH-R peptide 37 (ISRIYVSIDATLSQLES: 37m) using a computer 2 algorithm. In 37m, amino acids in position 5 and 8 were altered from those in hTSH-R peptide 37 3 (ISRIYVSIDVTLQQLES)( 6 ). 37m was expected to bind to HLA-DR3 firmly, but not bind well 4 to TCR.
5
In the current study, 1) we demonstrate distributions and characteristics of anti-hTSH-R-6 ECD antibodies in DR3 transgenic mice immunized to hTSH-R-ECD protein or peptides, 2) and we 7 demonstrate inhibitory effects of mutant hTSH-R peptide to B-cell and T-cell reactions. We seek 8 the possibility of an immunological treatment for GD, based on epitope recognition in DR3 9 transgenic mice. Forty-one 14-20mer hTSH-R-ECD peptides were synthesized as previously described ( 6 ).
Materials and Methods

10
Peptides 32-41 were predicted to have high binding affinity to HLA-DR3 or multiple HLA-DRs, 11 based on EpiMatrix program analysis( 4,6 ). In addition, a mutated hTSH-R-ECD peptide 37, 12 named 37m (ISRIYVSIDATLSQLES) was generated. This peptide has two sites of mutation 13 (peptide-DR3 binding position 5 :V to A,and 8: Q to S ) intended to diminish the peptide binding 14 affinity to TCR( 10 When DR3 transgenic mice were immunized to hTSH-R peptide 32,a less immunogenic 11 peptide, 50% of mice developed anti-hTSH-R-ECD antibody measured on ELISA( and 36), many the same as with hTSH-R peptide 37) (Fig.1C ).
15
We also checked antibody response by using non-hTSH-R peptides, and none of the 16 peptides bound anti hTSH-R peptides or protein antibodies. Further, cross reaction (one peptide 17 inhibiting binding to a different peptide) also was not seen. In PBS immunized mice, antisera did 18 not react with hTSH-R-ECD protein or peptides ( Fig.1D ). Serum TSH value (96.42+-52.35 mIU/l) 19 and T4 concentration (4.82+-0.31 ug/dl) were normal in these mice.
20
We compared the number of sequence differences between mice / human peptides to 21 ELISA OD450mm values, and no correlation was found in any group of mice (data not shown ).
Effect of peptide 37m on immunity induced by hTSH-R-ECD or hTSH-R 37 23 hTSH-R peptide 37 (AA 78-94) is an important immunogenic peptide in DR3 transgenic mice ( 4-6 ). Based on an informatics analysis we have identified the 9-mer frame at amino acid 1 position 83 as the most likely restricting element. In order to test our theory we designed a mutant 2 peptide which retains its specificity for DR3 but which lacks the outward facing contour recognized 3 by T cells reacting to hTSH-R peptide 37. The mutant peptide (ISRIYVSIDATLSQLES: 37m) has 4 been modified at positions 87 (V87A) and 90 (Q90S); TCR facing positions 5 and 8 within the 5 restricting 9-mer. In both cases the native amino acid was replaced by another amino acid having 6 similar chemical properties but less bulk. 7 37m was predicted to bind to HLA-DR3, but not bind to TCR. To confirm binding 8 affinity, EpiMatrix computer algorithm predicted a binding z-score of 37m (z=2.05) to DR3, the 9 same as hTSH-R peptide 37. Further, in vitro peptide binding assay using our standard method ( 4 10 ), showed IC 50 of 37m to DR3 was 0.3 uM and similar to IC 50 of hTSH-R peptide 37.
11
Anti hTSH-R protein antibody and anti hTSH-R peptide 37 antibodies were measured with 12 ELISA (Fig.2 ). Co immunization of 37m with hTSH-R peptide 37 did not inhibit development of 13 antibodies reacting to hTSH-R-ECD). Mice immunized to hTSH-R peptide 37 produced anti 14 hTSH-R peptide 37 antibody, however, mice immunized with hTSH-R peptide 37 and 37m did not 15 develop anti hTSH-R peptide 37 antibody (P<0.01). No mouse in any group, including mice 16 immunized only to 37m, developed antibody for 37m.
17
We also evaluated T-cell responses in splenocytes of DR3 transgenic mice immunized with 18 hTSH-R-ECD protein or hTSH-R-ECD peptides by proliferation assays (Fig.3 ). Reaction of 19 splenocyte to hTSH-R peptide 37 was not inhibited in mice immunized to hTSH-R-ECD protein 20 together with 37m, or mice immunized to hTSH-R-ECD (NS). Reaction of splenocytes to hTSH-21 R peptide 37 was significantly reduced in mice co-immunized to hTSH-R peptide 37 plus 37m, 22 compare to mice immunized to hTSH-R peptide 37 alone, when using 10ug of antigen ( all responses to epitopes were strongly inhibited by adding the same peptide to the wells (Fig.1A ).
13
Antisera raised to hTSH-R peptide 37 showed binding to the same peptides to which hTSH-14 R-ECD protein antisera bound, and also unrelated hTSH-R peptides (Fig.1B) . Comparing 15 antisera for mice immunized to hTSH-R-ECD, to those immunized to hTSH-R peptide 37, (Fig.1B It is difficult to explain with certainty why hTSH-R peptide 37 induced antibodies reacting 23 with multiple non-related TSH-R peptides. We hypothesize that the immunization induced antibodies reacting with host (mouse) TSH-R, which then led to antisera binding to a broad 1 spectrum of mTSH-R epitopes, which overlapped binding with anti-hTSH-R-ECD responses.
2 Otherwise it is difficult to understand how the mice could have developed responses to TSH-R 3 peptides to which the animals were not exposed. Antisera of mice immunized to hTSH-R peptide 4 32 reacted weakly to multiple hTSH-R peptides (Fig.1C) , supporting the idea that hTSH-R peptide 5 32 is a low immunogenic peptide( 4-6 ). 
9
The amino acid residue homology between mouse TSH-R and human TSH-R is 86.25%.
10
Among our synthesized hTSH-R peptides, peptide 13, 19, 21, 22, 23, 34, 40, and 41 have identical 11 amino acid sequences to mouse TSH-R. Other hTSH-R peptides have one or more differences 12 from mouse TSH-R sequences ( Table 1) . We compared the number of differences between mice / 13 human peptides to ELISA OD450mm values, and no correlation was found in any mice, suggesting 14 no relationship between the difference in species and the ability to produce antibodies (data not 15 shown). In the experiment using 37m, production of anti hTSH-R antibody in the mice immunized 2 to hTSH-R-ECD protein was not suppressed by the presence of 37m (Fig.2) . However, anti-3 hTSH-R peptide 37 antibody induced by hTSH-R peptide 37 immunization was significantly 4 inhibited when immunized together with 37m (Fig.2) . This suggested that B-cell function induced 5 with hTSH-R peptide 37 was partially suppressed, by competitive binding of 37m to HLA-DR3, 6 and thus reducing presentation of peptide 37 to TCR.
7
In our current study, splenocytes from mice immunized to hTSH-R-ECD reacted to hTSH-8 R-ECD, and the reaction was not inhibited with addition of 37m (Fig.3) . In contrast, splenocyte 9 reaction to hTSH-R peptide 37 from mice immunized to hTSH-R peptide 37 was significantly 10 reduced with addition of 37m (Fig.3) . The reason for this is considered to be an effect of 11 competitive binding inhibition of 37m described above. This fact supports another study using 12 mutant peptides having inhibitory effect for cell proliferation ( 13 ).
13
In our previous report on AITD, hTSHR-ECD induced T-cell response strongly to hTSH-R 14 peptide 37 and weakly to hTSH-R peptide 41 by 2 weeks ( 5 ). Further, 4 weeks after 15 immunization, B-cell produced antibodies to multiple hTSH-R peptides (Fig.1A) , while T-cells 16 responded preferentially to hTSH-R peptide 37 ( 5 ). This suggests that B-cell epitope spreading progressed more rapidly than T-cell epiope spreading. Similarly, hTSH-R peptide 37 18 immunization induced T-cell response only to hTSH-R peptide 37 in 4 weeks( 5 ), but drove B-cell 19 to produce antibodies to multiple peptides (Fig.1B) . This also supports the idea that B-cell epitope 20 spreading occurs earlier than T-cell epitope spreading in this study. 
